Like much of the federal government, the Food and Drug Administration has faced several program cuts and changes under the Trump administration’s sweeping changes to the bureaucracy.

In the most recent round of cuts, various senior negotiators at the FDA who talk with pharmaceutical companies to renew user fee programs that fund the drug review system were laid off, per a report from Reuters.